GlassScriptPhysician profile
Michael L Francisco
NPI 1871558239
$4,202.41
in general payments reported to CMS, 2019-2025
45 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $226 · 2021: $344 · 2022: $533 · 2023: $1,298 · 2024: $538 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.50 |
| Education | $101.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $567.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $461.49 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $389.42 | 2019-2025 | Opdivo, Opdualag |
| Genzyme Corporation | $320.88 | 2019-2023 | |
| Janssen Biotech, INC. | $296.76 | 2019-2024 | Darzalex, Rybrevant, Tecvayli |
| Pfizer INC. | $277.16 | 2019-2025 | |
| Lilly USA, LLC | $143.21 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $141.17 | 2019-2023 | Lynparza, Keytruda |
| Astellas Pharma US INC | $125.35 | 2019-2023 | Padcev |
| Amgen INC. | $121.68 | 2019-2022 | |
| Abbvie INC. | $117.88 | 2019-2025 | |
| Daiichi Sankyo INC. | $104.22 | 2020-2023 | Enhertu |
| Seagen INC. | $96.52 | 2019-2023 | Adcetris |
| Emd Serono, INC. | $89.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $79.61 | 2023-2024 | Ojjaara, Jemperli, Zejula |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Francisco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.